Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFIRI/FOLFOX in KRAS wt mCRC (APEC)
NCT00778830Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2009
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Best Overall Confirmed Response Rate. Started Feb 2009; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00778830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778830.